Bausch & Lomb appoints Merck's Alex Kelly VP
This article was originally published in Scrip
Executive Summary
Global eye health company Bausch & Lomb has appointed Alex Kelly vice-president of investor relations, reporting to president and CFO Bob Bertolini. Kelly joins the company from Merck & Co, where he most recently served as vice-president of investor relations. Prior to Merck he was group vice-president of global communications and investor relations at Schering-Plough.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.